Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$101K Sell
6,544
-1,337
-17% -$22.3K ﹤0.01% 1345
2025
Q4
$142K Buy
7,881
+183
+2% +$3.15K ﹤0.01% 1146
2025
Q3
$124K Buy
7,698
+575
+8% +$8.41K ﹤0.01% 1191
2025
Q2
$77.6K Sell
7,123
-2,399
-25% -$26.9K ﹤0.01% 1356
2025
Q1
$119K Buy
9,522
+455
+5% +$7.5K ﹤0.01% 1119
2024
Q4
$180K Buy
9,067
+3,561
+65% +$39.4K ﹤0.01% 919
2024
Q3
$45K Buy
5,506
+3,099
+129% +$21K ﹤0.01% 1636
2024
Q2
$16.4K Buy
+2,407
New +$16.5K ﹤0.01% 2058
2023
Q4
Sell
-897
Closed -$2.21K 3215
2023
Q3
$2.21K Sell
897
-4,531
-83% -$21.7K ﹤0.01% 2745
2023
Q2
$42.4K Buy
5,428
+3,615
+199% +$25.8K ﹤0.01% 1523
2023
Q1
$11.9K Buy
1,813
+2
+0.1% +$13 ﹤0.01% 2128
2022
Q4
$10.5K Buy
1,811
+1,643
+978% +$10.3K ﹤0.01% 2119
2022
Q3
$1K Buy
+168
New +$1.01K ﹤0.01% 2991
2022
Q2
Sell
-367
Closed -$3K 3257
2022
Q1
$3K Sell
367
-55
-13% -$468 ﹤0.01% 2698
2021
Q4
$4K Sell
422
-332
-44% -$3.86K ﹤0.01% 2492
2021
Q3
$9K Buy
754
+691
+1,097% +$9.59K ﹤0.01% 2121
2021
Q2
$1K Buy
63
+29
+85% +$455 ﹤0.01% 2768
2021
Q1
$1K Buy
+34
New +$642 ﹤0.01% 2643

Other funds holding MESO

SignatureFD's MESO Position: Q1 2026 in Review

SignatureFD reduced its Mesoblast (MESO) stake by 17% in Q1 2026, selling an estimated $22.3K and leaving 6,544 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #1345.

SignatureFD first reported a position in MESO in Q1 2021 and has held it in 18 quarters since. The position peaked at $180K in Q4 2024. 69 funds tracked by Wall St. Rank hold MESO as of Q1 2026.

  • SignatureFD held 6,544 shares of Mesoblast worth $101K as of Q1 2026.
  • SignatureFD sold 1,337 Mesoblast shares in Q1 2026, an estimated $22.3K.
  • Mesoblast made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #1345 holding.
  • SignatureFD first reported a position in Mesoblast in Q1 2021 and has held it in 18 quarters since.
  • SignatureFD's Mesoblast position peaked at $180K in Q4 2024.
  • 69 funds tracked by Wall St. Rank held Mesoblast as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.